Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 4
2016 4
2018 5
2019 5
2020 6
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.
Morales-Cano D, Barreira B, Callejo M, Olivencia MA, Ferruelo A, Milara J, Lorente JÁ, Moreno L, Cogolludo Á, Perez-Vizcaino F. Morales-Cano D, et al. Among authors: callejo m. Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print. Vascul Pharmacol. 2024. PMID: 38599357
Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F, Moreno L. Morales-Cano D, et al. Among authors: callejo m. Front Pharmacol. 2023 Jun 12;14:1228923. doi: 10.3389/fphar.2023.1228923. eCollection 2023. Front Pharmacol. 2023. PMID: 37377931 Free PMC article.
Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension.
Blanco I, Marquina M, Tura-Ceide O, Ferrer E, Ramírez AM, Lopez-Meseguer M, Callejo M, Perez-Vizcaino F, Peinado VI, Barberà JA. Blanco I, et al. Among authors: callejo m. Front Pharmacol. 2023 Apr 24;14:1145994. doi: 10.3389/fphar.2023.1145994. eCollection 2023. Front Pharmacol. 2023. PMID: 37188265 Free PMC article.
Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F, Moreno L. Morales-Cano D, et al. Among authors: callejo m. Front Pharmacol. 2023 Mar 29;14:1021535. doi: 10.3389/fphar.2023.1021535. eCollection 2023. Front Pharmacol. 2023. PMID: 37063275 Free PMC article.
Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats.
Olivencia MA, Esquivel-Ruiz S, Callejo M, Mondéjar-Parreño G, Quintana-Villamandos B, Barreira B, Sacedón R, Cogolludo Á, Perros F, Mendes-Ferreira P, Pérez Vizcaíno F. Olivencia MA, et al. Among authors: callejo m. Am J Respir Cell Mol Biol. 2022 Sep;67(3):402-405. doi: 10.1165/rcmb.2022-0001LE. Am J Respir Cell Mol Biol. 2022. PMID: 36047774 No abstract available.
Hepatic Encephalopathy-Associated Cerebral Vasculopathy in Acute-on-Chronic Liver Failure: Alterations on Endothelial Factor Release and Influence on Cerebrovascular Function.
Caracuel L, Sastre E, Callejo M, Rodrigues-Díez R, García-Redondo AB, Prieto I, Nieto C, Salaices M, Aller MÁ, Arias J, Blanco-Rivero J. Caracuel L, et al. Among authors: callejo m. Front Physiol. 2020 Nov 20;11:593371. doi: 10.3389/fphys.2020.593371. eCollection 2020. Front Physiol. 2020. PMID: 33329042 Free PMC article.
32 results